Beamerella Knight and Hambletoniola Carvalho

13 p. : ill. ; 26 cm.Includes bibliographical references (p. 13)."Larinocerus Froeschner is synonymized with Beamerella Knight. Beamerella and its two included species personatus Knight and balius Froeschner are redescribed as are Hambletoniola Carvalho and its single included species antennata Carvalho. A key to included genera and species as well as illustrations of the male and female genitalia, trichobothria, and pretarsal structures are provided. An asymmetrical 'lateral tube' is newly described for the female ganitalia of Beamerella and Hambletoniola; its occurrence is documented for some other Phylini. The interrelationships of the three taxa and their relationship to other Phylini are discussed"--P. [1]

Progress in D-brane model building

The state of the art in D-brane model building is briefly reviewed, focusing on recent achievements in the construction of D=4 N = 1 type II string vacua with semi-realistic gauge sectors. Such progress relies on a better understanding of the spectrum of BPS D-branes, the effective field theory obtained from them and the explicit construction of vacua. We first consider D-branes in standard Calabi-Yau compactifications, and then the more involved case of compactifications with fluxes. We discuss how the non-trivial interplay between D-branes and fluxes modifies the previous model-building rules, as well as provides new possibilities to connect string theory to particle physics.Comment: Using w-art.cls, 27 pages, 6 figures. Based on a talk given at the RTN `Constituents, Fundamental Forces and Symmetries of the Universe' Workshop and Midterm meeting in Napoli, October 2006. v2: typos corrected and references adde

Hundreds of variants clustered in genomic loci and biological pathways affect human height

Most common human traits and diseases have a polygenic pattern of inheritance: DNA sequence variants at many genetic loci influence the phenotype. Genome-wide association (GWA) studies have identified more than 600 variants associated with human traits, but these typically explain small fractions of phenotypic variation, raising questions about the use of further studies. Here, using 183,727 individuals, we show that hundreds of genetic variants, in at least 180 loci, influence adult height, a highly heritable and classic polygenic trait. The large number of loci reveals patterns with important implications for genetic studies of common human diseases and traits. First, the 180 loci are not random, but instead are enriched for genes that are connected in biological pathways (P = 0.016) and that underlie skeletal growth defects (P < 0.001). Second, the likely causal gene is often located near the most strongly associated variant: in 13 of 21 loci containing a known skeletal growth gene, that gene was closest to the associated variant. Third, at least 19 loci have multiple independently associated variants, suggesting that allelic heterogeneity is a frequent feature of polygenic traits, that comprehensive explorations of already-discovered loci should discover additional variants and that an appreciable fraction of associated loci may have been identified. Fourth, associated variants are enriched for likely functional effects on genes, being over-represented among variants that alter amino-acid structure of proteins and expression levels of nearby genes. Our data explain approximately 10% of the phenotypic variation in height, and we estimate that unidentified common variants of similar effect sizes would increase this figure to approximately 16% of phenotypic variation (approximately 20% of heritable variation). Although additional approaches are needed to dissect the genetic architecture of polygenic human traits fully, our findings indicate that GWA studies can identify large numbers of loci that implicate biologically relevant genes and pathways.

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy